Invest in Arcade Therapeutics, Inc.

We are excited to launch this Advocates Round, offering behavioral health providers, healthcare professionals, and advocates for improved mental health care the opportunity to become owners in Arcade alongside our larger investors, at the same terms.

We expect to increase our company valuation in our next round as we meet our deployment targets over the next 6-12 months, and as new Digital Mental Health Treatment reimbursement codes become widely available in 2025. We believe meaningful change in healthcare requires active participation from those on the front lines of care, and those who wish to advocate for new ideas. We welcome you to join us as investors and partners in our journey!

Today, we are failing to reach many people in need of help.  70% of primary care visits are related to mental health conditions, yet doctors don't have enough options to start engaging patients in these settings. This leads to a large percentage of patients not seeking care, along with a large undiagnosed population left struggling with their mental health.

Sources: HHS, CDC, NIH, Project Hope

190M Americans play video games today, according to the Entertainment Software Association.

Mobile games are most popular with adults, and allow for access anytime, anywhere and are used by all cultural backgrounds.

Arcade's Co-Founders bring together world-class scientific knowledge with experience building consumer products across healthcare, media and tech-enabled services. We've added amazing advisors to the team that bring game strategy, regulatory, and commercial expertise to support our goals.

Our unique approach to subconscious cognitive training is embedded into game play.  Our method is refined and tested over years of NIH-Funded clinical trials, which are published in peer reviewed journals.

Attention Bias Modification:

• Targets subconscious processing
• Complements traditional CBT
• Has a low time-demand on already burdened patients



Our first game StarStarter for Anxiety has now launched through qualified enterprise and community partners. It's available to help manage symptoms of anxiety as a first-line treatment or complementary to other treatments.

Our most recent clinical trial delivered excellent results within a 30 day treatment timeframe, showing similar effectiveness to pharmaceutical products but without the side effects. You can find more information about this trial and our other published studies at https://arcadetherapeutics.com/research/

Our go to market strategy is to partner with qualified organizations to make our treatments available to specific populations. We have contracted with initial partners in primary care, tele-health, universities that serve marginalized and underserved groups where mental health care is less accessible. In certain care settings we can support billing requirements for care providers to bill for related codes such as Remote Therapeutic Monitoring (RTM).

Sources: NIMH, Best Colleges, NEA, Commonwealth

Our products come with an integrated clinical platform for secure registration, periodic assessments, and data management to support personalization and triage. In this way we can integrate with existing services to engage with patients earlier, and provide escalation paths that help them take appropriate next steps.

In other exciting news, we were co-awarded a $3.8M grant from the NIMH with UT Austin to fund a clinical trial for our next treatment for Major Depressive Disorder. This new product has already been piloted, and has shown promising results.

Meanwhile, CMS has for the first time introduced Medicare reimbursable codes for "digital mental health treatment (DMHT) devices" as a physician service. This groundbreaking change will allow new and better reimbursement pathways for digital health products. It is especially beneficial for companies like ours who have built up years of clinical evidence for their treatments.

Our projected revenue is based on deployments across our priority segments, using scaling pricing starting at $75 per treatment for non-prescription anxiety to approximately $300 for depression treatment. We also intend to license these products into international markets. The additional opportunity of combination products to improve effectiveness of pharmaceutical products is not fully captured yet as this is a new and rapidly evolving opportunity.

Future projections are not guaranteed.

Our Advocates Round will be used to support early rollouts of our treatments through trusted organizations to people in need, along with support for FDA Clearances that support our long term goals of making effective treatments available in scale. 

Funds will be used to execute on revenue and product deployment milestones to achieve early revenue scale of $1MM-$2MM ARR prior to Series A

• Non-prescription Anxiety launches. Primary Care, Universities, BH and Tele-Therapy segments
• Core Operations and Client Support. Support for client operations and sales to achieve penetration targets. Maintenance of technology and game development.
• FDA Submission Process for Depression. Clinical trial and FDA submission support for of ABM-02 (Depression) being managed by UT Austin with $3.8M NIMH Grant. 
• Licensing and Co-Development for Expanded Opportunities. Support for pharma combination opportunities, international licensing and co-development leveraging our IP and game development capabilities.

Investors: